Cullinan oncology and taiho pharmaceutical complete agreement for strategic collaboration to jointly develop and commercialize cln-081/tas6417

Cullinan oncology receives upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments
CGEM Ratings Summary
CGEM Quant Ranking